To Avoid The Fate Of Pcsk9 Inhibitors Repatha (Evocolumab) And Praluent (Alirocumab), Which Have Muddled Through Underwhelming Launches In Recent Years, Novartis Pharmaceuticals President Marie-France Tschudin Said The Company Plans To Work Directly With The Top 200 Hospital Systems In The Us To Identify Patients Who Would Be Most Likely To Benefit From Leqvio (Inclisiran). Time Will Tell Whether Its Launch Strategy Will Translate Into Improved Uptake Versus The Pcsk9 Drugs That Came Before It. What HappenedThe Fda Approved Leqvio, A Pcsk9-Targeting Sirna Therapy, To Lower Ldl Cholesterol. Leqvio Is Administered Twice Per Year After Two Initial Doses Within The First Three Months Of Treatment. Novartis Plans To Launch The Drug In Early January 2022 At $3,250 Per Dose, Which Would Be $9,750 The First Year And $6,500 In Subsequent Years. The BackstoryWhile The Fda Issued A Complete Response Letter For Leqvio In December 2020, Citing An Inspection Issue At A Third-Party Manufacturing Facility, Analysts And Physicians Largely Believe The Molecule Could Change The Way High Cholesterol Is Treated Given The Convenience Of Its Twice-Yearly Dosing Profile. Many Analysts Think Novartis Overpaid To Acquire Leqvio
